J3399 HCPCS Level II code: Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes

J3399 is the HCPCS code for “Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

J3399

Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes

Short description: Inj onase abepar-xioi treat

HCPCS · United States

Medicare details

The indicators CMS publishes with J3399 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Carrier judgment
Medicare pricing
Drugs
Type of service
Medical care; Lump sum purchase of DME, prosthetics, orthotics
BETOS category
Other drugs
Added
Jul 1, 2020

Where J3399 sits

  1. 1J codesDrugs administered other than orally
  2. 2Active code J3399Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code J3399 mean?

J3399 is the HCPCS code for “Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover J3399?

CMS lists J3399’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.